Pharming Group (NASDAQ:PHAR) Short Interest Up 107.1% in March

Pharming Group (NASDAQ:PHAR) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 5,800 shares, a growth of 107.1% from the February 28th total of 2,800 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 6,700 shares, the days-to-cover ratio is currently 0.9 days.

Analyst Ratings Changes

A number of research analysts have recently commented on PHAR shares. HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th. Jefferies Financial Group began coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 price objective on the stock. Finally, Oppenheimer raised their target price on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research note on Friday, March 14th.

Pharming Group Stock Down 3.2 %

Shares of PHAR stock traded down $0.27 during mid-day trading on Friday, reaching $8.38. 5,632 shares of the company were exchanged, compared to its average volume of 6,202. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The business’s 50 day simple moving average is $8.80 and its 200 day simple moving average is $8.66. The company has a market capitalization of $569.83 million, a P/E ratio of -32.22 and a beta of -0.10. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $11.30.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). The company had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Research analysts predict that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.